ストックスクリーナーアプリを入手
14.41
9.51%
-1.565
前日終値:
$15.98
開ける：
$15.9
24時間の取引高:
651.92K
Relative Volume:
1.01
時価総額：
$729.98M
収益：
$89.04M
当期純損益:
$-241.08M
株価収益率:
-2.7405
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
+6.17%
1か月 パフォーマンス:
+0.77%
6か月 パフォーマンス:
+59.08%
1年 パフォーマンス:
+81.89%
1日の値動き範囲:
$14.31
$16.00
1週間の範囲:
$13.40
$16.19
52週間の値動き範囲:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
RGNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
14.42 | 808.96M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.16 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.89 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.50 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.90 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.94 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | ダウングレード | Goldman | Buy → Neutral |
| 2025-02-07 | 再開されました | Raymond James | Outperform |
| 2024-11-15 | 再開されました | Morgan Stanley | Overweight |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-06-07 | 開始されました | Goldman | Buy |
| 2024-03-11 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-08 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 再開されました | Raymond James | Outperform |
| 2023-11-01 | 開始されました | Stifel | Buy |
| 2023-06-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Wedbush | Neutral |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-01-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-14 | 再開されました | Raymond James | Outperform |
| 2019-06-05 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-25 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-02-05 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-11-08 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-08-08 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-23 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-05-09 | 繰り返されました | Barclays | Overweight |
| 2018-04-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 開始されました | Mizuho | Neutral |
| 2017-11-09 | 再開されました | Morgan Stanley | Overweight |
すべてを表示
Regenxbio Inc (RGNX) 最新ニュース
Gene Therapy Market Outlook 2026-2031, Featuring Profiles - GlobeNewswire
REGENXBIO (NASDAQ:RGNX) Sets New 12-Month HighWhat's Next? - MarketBeat
Wet Age-Related Macular Degeneration Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research, Qilu - Barchart.com
REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey
Aug Sectors: Is REGENXBIO Inc stock a good dividend stockWatch List & Weekly Breakout Watchlists - baoquankhu1.vn
Aug Catalysts: Why is REGENXBIO Inc stock going upSwing Trade & Stepwise Trade Signal Guides - baoquankhu1.vn
Street Watch: Is REGENXBIO Inc impacted by rising ratesQuarterly Portfolio Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Regenxbio Shares Retreat as Market Digests Conflicting Signals - AD HOC NEWS
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
REGENXBIO (NASDAQ:RGNX) Stock Price Down 6.7%What's Next? - MarketBeat
Patients Treated With REGENXBIO’s DMD Gene Therapy RGX-202 Exceed Expected Disease Trajectory on NSAA - Neurology Live
Is REGENXBIO Inc in a long term uptrendPrice Action & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
RGNX: Pivotal data and regulatory milestones in Duchenne, wet AMD, and Hunter programs drive a transformative year - TradingView — Track All Markets
RGNX: Late-stage gene therapy programs show strong efficacy, safety, and commercial readiness for 2024 - TradingView — Track All Markets
$191.2 Million Achromatopsia Market Outlook, 2026-2032, - GlobeNewswire
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Is REGENXBIO Inc stock undervalued right nowJuly 2025 Highlights & Technical Pattern Based Buy Signals - baoquankhu1.vn
Technical Reactions to RGNX Trends in Macro Strategies - Stock Traders Daily
Macular Degeneration Treatment Market is expected to reach US$ - openPR.com
Hedge Fund Moves: What hedge fund activity signals for REGENXBIO Inc. stockMarket Sentiment Review & Fast Exit and Entry Trade Guides - Bộ Nội Vụ
Lobbying Update: $60,000 of REGENXBIO INC. lobbying was just disclosed - Quiver Quantitative
Market Overview: Is REGENXBIO Inc stock undervalued right now2025 Price Action Summary & Fast Gain Swing Alerts - baoquankhu1.vn
REGENXBIO (NASDAQ:RGNX) Shares Gap UpShould You Buy? - MarketBeat
Regenxbio (RGNX) Shares Rise on Promising Duchenne Therapy Data - GuruFocus
Regenxbio stock maintains Buy rating at H.C. Wainwright on positive DMD trial data - Investing.com Australia
REGENXBIO Stock Hits New High On Duchenne Trial DataWill 2026 Be A Transformative Year? - RTTNews
Regenxbio stock rating reiterated at Outperform by Baird on positive RGX-202 data - Investing.com South Africa
REGENXBIO (RGNX) Advances Gene Therapy Pipeline for Future Miles - GuruFocus
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program - Chartmill
Aug PostEarnings: How REGENXBIO Inc stock performs during Fed tightening cycles2025 Major Catalysts & Smart Investment Allocation Tips - moha.gov.vn
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a 107% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Why REGENXBIO Inc. stock is trending among retail traders2025 Volume Leaders & Safe Capital Growth Stock Tips - Улправда
What hedge fund activity signals for REGENXBIO Inc. stockMarket Performance Report & Safe Swing Trade Setup Alerts - Улправда
Why REGENXBIO Inc. stock is recommended by analystsPortfolio Gains Report & Growth Focused Entry Reports - ulpravda.ru
How REGENXBIO Inc. stock trades during market volatilityJuly 2025 Levels & Daily Chart Pattern Signal Reports - Улправда
Is REGENXBIO Inc. stock gaining market share2025 Institutional Moves & Low Risk High Reward Ideas - ulpravda.ru
How REGENXBIO Inc. stock benefits from global expansionDividend Stock Watch & Start Your Free Trading Journey Today - ulpravda.ru
REGENXBIO (NASDAQ:RGNX) Sets New 1-Year HighStill a Buy? - MarketBeat
RegenXBio (RGNX) Gets a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Raises Price Target on REGENXBIO to $28 From $20, Maintains Buy Rating - marketscreener.com
RegenXBio’s RGX-202: Promising Long-term Study for Duchenne Muscular Dystrophy - MSN
REGENXBIO updates Phase 1/2 data for Duchenne candidate - msn.com
Trading the Move, Not the Narrative: (RGNX) Edition - Stock Traders Daily
Prospects for Regenxbio’s clemidsogene lanparvovec approval in Hunter syndrome - The Pharma Letter
REGENXBIO (NASDAQ:RGNX) Trading Down 3.8%Here's Why - MarketBeat
Regenxbio (RGNX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Regenxbio Inc (RGNX) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.05%
大文字化:
|
ボリューム (24 時間):